MktsMarkets

Candel Therapeutics, Inc.
NASDAQ: CADLKey statistics
CADL News
Stories mentioning CADL from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 9,840 | 11,028 | 8,461 | 6,991 | 4,016 | 4,817 | 5,416 | 4,979 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 16,284 | 15,752 | 13,207 | 11,177 | 8,130 | 8,141 | 8,757 | 8,571 |
| Operating Income (Loss) | (16,284) | (15,752) | (13,207) | (11,177) | (8,130) | (8,141) | (8,757) | (8,571) |
| Interest Income | 240.00 | |||||||
| Interest Expense | 1,564 | 1,416 | 161.00 | 236.00 | 306.00 | 390.00 | 487.00 | 567.00 |
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (8,861) | (29,496) | (11,269) | (4,796) | 7,379 | (14,073) | (10,646) | (22,237) |
| Earnings Per Share (Basic) | (0.14) | (0.56) | (0.21) | (0.09) | 0.15 | (0.44) | (0.33) | (0.74) |
| Earnings Per Share (Diluted) | (0.14) | (0.56) | (0.21) | (0.09) | 0.13 | (0.44) | (0.33) | (0.74) |
| Weighted Average Shares Outstanding (Basic) | 62,362 | 52,959 | 54,894 | 51,490 | 50,482 | 31,675 | 32,014 | 29,878 |
| Weighted Average Shares Outstanding (Diluted) | 62,362 | 52,959 | 54,894 | 51,490 | 54,766 | 31,675 | 32,014 | 29,878 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About CADL
Candel Therapeutics, Inc. (NASDAQ: CADL) is a stock listed on the Nasdaq Stock Market under the ticker symbol CADL. It last traded at $5.40 (Nov 17, 2026, 4:00 PM ET), down 7.1% on the day. That gives Candel Therapeutics a market capitalisation of $423.6M.
Over the past 52 weeks CADL has traded between $4.35 and $14.00.
For the quarter ended Mar 31, 2026 it reported a net loss of $8.9M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$8.9M |
| Dec 31, 2025 | — | -$29.5M |
| Sep 30, 2025 | — | -$11.3M |
| Jun 30, 2025 | — | -$4.8M |
From Candel Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…